Hesham Mohamed
YOU?
Author Swipe
View article: Odronextamab treatment for patients with rare subtypes of relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL): Updated efficacy and safety analyses from a dedicated cohort of the ELM-2 study
Odronextamab treatment for patients with rare subtypes of relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL): Updated efficacy and safety analyses from a dedicated cohort of the ELM-2 study Open
Introduction Aggressive B-NHL includes rare subtypes such as transformed diffuse large B-cell lymphoma (t-DLBCL), high-grade B-cell lymphoma not otherwise specified (HGBL NOS), primary mediastinal B-cell lymphoma (PMBL), and follicular lym…
View article: Odronextamab plus chemotherapy in patients with previously untreated follicular lymphoma: First results from part 1 of the Phase 3 Olympia-2 study
Odronextamab plus chemotherapy in patients with previously untreated follicular lymphoma: First results from part 1 of the Phase 3 Olympia-2 study Open
Introduction Odronextamab (Odro), a CD20×CD3 bispecific antibody, showed promising efficacy as first-line monotherapy for patients (pts) with previously untreated follicular lymphoma (FL) in Part 1 of the ongoing Phase 3 OLYMPIA-1 study (N…
View article: Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL
Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL Open
Odronextamab, a CD20×CD3 bispecific antibody, demonstrated robust efficacy and durable responses, with a generally manageable safety profile, in patients with relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (…
View article: Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy Open
In the ELM-2 study (NCT03888105) of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (n = 141), odronextamab 160 mg weekly (after step-up dosing) significantly improved Functional Assessment of Cancer Therapy-Lym…
View article: Assessment of navigation bronchoscopy with rapid on-site evaluation technique in detection of peripheral lung lesions
Assessment of navigation bronchoscopy with rapid on-site evaluation technique in detection of peripheral lung lesions Open
Background Diagnosing peripheral pulmonary lesions (PPLs) poses significant challenges due to their often-inaccessible location beyond conventional bronchoscopy reach. The integration of virtual navigation bronchoscopy (VBN) with rapid on-…
View article: Bariatric Surgery and Lung Transplant Outcomes: Case Series and Insights from a Propensity-Matched Analysis at a High-Volume Transplant Center
Bariatric Surgery and Lung Transplant Outcomes: Case Series and Insights from a Propensity-Matched Analysis at a High-Volume Transplant Center Open
Background An increasing number of patients with a history of bariatric surgery and advanced respiratory disease are presenting for lung transplantation (LTx). We aimed to describe and compare LTx outcomes between recipients with prior bar…
View article: Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review
Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review Open
Objectives The objective of this systematic literature review (SLR) combined with expert clinical review was to identify and rank prognostic factors and effect measure modifiers (EMMs) systematically and comprehensively in patients with re…
View article: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial Open
The phase 2, multicohort, ongoing ELM-2 study evaluates odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma after ≥2 lines of therapy. Here primary analysis of the diffuse la…
View article: Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study Open
Patients with relapsed/refractory diffuse large B-cell lymphoma progressing after chimeric antigen receptor T-cell (CAR-T) therapy have dismal outcomes. The prespecified post–CAR-T expansion cohort of the ELM-1 study investigated the effic…
View article: Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Open
Introduction Severe infections and cytokine release syndrome (CRS) are commonly observed following treatment with T-cell-engaging therapies such as CAR-T therapies and CD3-targeting bispecific antibodies (bsAbs). The CAR-HEMATOTOX model in…
View article: Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study
Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study Open
Introduction Patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL) experience progressively worse outcomes with each successive line of therapy; complete response (CR) rates are 44% with third-line (3L), 27% with 4L, and 2…
View article: Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies Open
Introduction Odronextamab, a novel, investigational, CD20×CD3 bispecific antibody, has demonstrated compelling efficacy and a generally manageable safety profile in heavily pretreated patients with relapsed/refractory (R/R) diffuse large B…
View article: Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab in the ELM-2 Study
Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab in the ELM-2 Study Open
Introduction Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of B-cell non-Hodgkin lymphoma (B-NHL). Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard of care for the first-line …
View article: Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab
Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab Open
Introduction The optimal duration of treatment with bispecfic antibodies in the setting of relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) has not been prospectively determined. In the Phase 2 ELM-2 study (NCT03888105), odron…
View article: Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab
Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab Open
Introduction Severe infections and cytokine release syndrome (CRS) are adverse events commonly observed following treatment with T-cell-engaging therapies such as CAR-T therapies and CD3-targeting bispecific antibodies (bsAbs). The CAR-HEM…